GenScript Bio (01548): CARVYKTI's fourth quarter trade sales revenue is approximately 334 million US dollars.

22/01/2025

GMT Eight

GENSCRIPT BIO (01548) announced that, based on the cooperation and licensing agreement entered into by Legend Biotech and Janssen Biotech, Inc. (Johnson & Johnson) on December 21, 2017, CARVYKTI is expected to generate approximately $334 million in trade sales revenue by the end of the quarter ending December 31, 2024.

"Positive on AI-driven 'strong' growth, investment bank Wedbush maintains Snowflake (SNOW.US) as 'outperforming the market' rating."

Partial directors and senior executives of NavInfo Co., Ltd. (002405.SZ) plan to reduce their holdings by a total of no more than 1,771,400 shares.

Contact: contact@gmteight.com

GenScript Bio (01548): CARVYKTI's fourth quarter trade sales revenue is approximately 334 million US dollars.

RECOMMEND

US Stock Market Move | Taiwan Semiconductor Manufacturing Co., Ltd. Sponsored ADR (TSM.US) rose more than 2%, hitting a new all-time high.

US Stock Market Move | Q4 earnings per share exceeded expectations, Anheuser-Busch InBev (APH.US) rose over 6%, reaching a new all-time high.

US Stock Market Move | AI concept stocks perform strongly, Arm Holdings (ARM.US) rises more than 14%.